PHI with Autoimmune hepatitis (AIH)
How does this condition affect your private health insurance?
Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease where the body's immune system mistakenly attacks its own liver cells. This leads to ongoing inflammation, cellular damage, and potentially scarring (fibrosis or cirrhosis) if left untreated. Symptoms are varied, ranging from mild fatigue and joint pain to more severe signs like jaundice, dark urine, and abdominal discomfort. AIH predominantly affects women and can manifest at any age. Diagnosis relies on blood tests for liver enzymes and autoantibodies, imaging studies, and a definitive liver biopsy. Treatment primarily involves immunosuppressive drugs such as corticosteroids and azathioprine to suppress the immune response, aiming to prevent further liver damage and disease progression.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months, often with insidious onset before diagnosis.
Duration of Illness (Lifetime)
Chronic; typically requires lifelong management and monitoring.
Cost of Treatment (Initial)
Approximately $5,000 - $20,000 for initial diagnosis (tests, biopsy) and starting medication.
Cost of Treatment (Lifetime)
Can range from $100,000 to over $500,000, including medication, regular monitoring, and potential management of complications or transplant.
Mortality Rate
Significant without treatment (high mortality rate); considerably reduced with effective, lifelong therapy, but still present due to cirrhosis or liver failure (e.g., 5-10% mortality over 10 years in treated patients).
Risk of Secondary Damages
High probability of developing cirrhosis, liver failure, portal hypertension, and increased risk of hepatocellular carcinoma, especially if untreated or poorly controlled.
Probability of Full Recovery
Low; remission is achievable with consistent treatment, but true 'cure' without the need for ongoing medication is rare. Relapses are common if treatment is stopped.
Underlying Disease Risk
Moderate to high probability of co-occurring other autoimmune diseases (e.g., celiac disease, thyroiditis, inflammatory bowel disease, rheumatoid arthritis, type 1 diabetes).